Objective: The aim of this study was to evaluate long-term safety, efficacy, and quality of life (QOL) of ≤400-mg/day USL255, Qudexy® XR (topiramate) extended-release capsules, as adjunctive therapy for partial-onset seizures (POS) in adults. Methods: Patients who completed the 11-week double-blind treatment phase of the phase 3 PREVAIL study were eligible to enroll in this 1-year open-label extension (OLE) study (PREVAIL OLE). The primary objective was to evaluate the safety and tolerability of USL255 (including treatment-emergent adverse events [TEAEs]). The secondary objective was to assess seizure frequency in patients (e.g., median percent reduction from baseline in weekly POS frequency, responder rate [proportion of patients with ≥25%, ≥50%, ≥75%, or 100% reduction from baseline in POS frequency], and seizure-free intervals [proportion of patients who were seizure-free for 4, 12, 24, 36, or 48 weeks]). Exploratory clinical-status endpoints included the Global Impression of Change (CGI-C) and Quality of Life in Epilepsy-Problems (QOLIE-31-P) questionnaires. Post hoc analyses evaluated neurocognitive TEAE incidences during the first 11 and entire 55 weeks of treatment and efficacy by patient age and drug-resistant status. Results: Of the 217 patients who completed PREVAIL (USL255, n = 103; placebo, n = 114), 210 (97%) enrolled in PREVAIL OLE and were included in the ITT population. Across the entire 55-week treatment period, USL255 was generally safe and well tolerated, with low individual neurocognitive TEAE incidences. Seizure reduction was sustained across the year-long study and observed in patient subgroups, including those with highly drug-resistant seizures and those ≥50 years of age. Improvements in CGI-C and QOLIE-31-P were also observed. Significance: The results of PREVAIL OLE are consistent with those from PREVAIL and demonstrate that adjunctive treatment with up to 400 mg/day of USL255 may be a safe and effective treatment option for a variety of adult patients with refractory POS.
Introduction
Up to 30% of patients with epilepsy still experience seizure activity despite antiepileptic drug (AED) treatment [1] , and seizures in others remain completely resistant to currently available treatments [2] . Uncontrolled seizures occur at severe psychosocial cost to patients [3] , who would benefit from any reduction in seizure activity. Extendedrelease formulations of AEDs are designed to reduce dosing frequency and maintain relatively consistent drug plasma concentrations, which may reduce breakthrough seizures, cognitive-related and other adverse events (AEs), and improve overall quality of life (QOL). USL255, Qudexy® XR (topiramate) extended-release capsules (Upsher-Smith, Maple Grove, MN, U.S.A. [4] ), is an extended-release, once-daily formulation of the well-established AED topiramate. USL255 is a proprietary multiparticulate (beads in a capsule) formulation, which was developed to deliver consistent drug release over a 24-h dosing interval. USL255 provides an overall plasma topiramate exposure that is equivalent to immediate-release topiramate but with a significantly lower maximum concentration (C max ) and higher minimum concentration (C min ), resulting in decreased fluctuations in drug plasma concentrations [5, 6] .
The efficacy and favorable tolerability of 200-mg/day USL255 as adjunctive therapy for partial-onset seizures (POS) were demonstrated in a randomized, double-blind, placebo-controlled, multicenter, 11-week phase 3 study (PREVAIL). A longer-term safety evaluation is important because certain TEAEs can be delayed, particularly when topiramate is used as add-on treatment [7] . Moreover, topiramate may be associated with neurocognitive-related treatment-emergent AEs (TEAEs) [8] that can continue over the long term [9, 10] . Therefore, this year-long openlabel extension (OLE) study (PREVAIL OLE) was conducted to evaluate the long-term safety and efficacy of ≤400-mg/day USL255 as adjunctive therapy for POS. In addition, post hoc analyses examining new onset (incidence) of neurocognitive TEAEs and seizure reduction in various patient subgroups were performed.
Methods

Trial conduct
The PREVAIL OLE study was conducted from October 2010 to March 2014 at 54 study centers in 15 countries (Argentina, Australia, Canada, Chile, Germany, Greece, Hungary, India, Israel, New Zealand, Poland, Russia, South Africa, Spain, and the United States). This study was conducted in accordance with the International Conference on Harmonization E6 Guideline for Good Clinical Practice and applicable regulatory requirements. The institutional review boards and the European Research Council supervised and safeguarded the rights, safety, and well-being of all study subjects. Prior to any screening procedures, all patients provided written informed consent. The PREVAIL OLE study is registered with ClinicalTrials.gov (NCT01191086).
Patients
Eligible patients were those who completed the 11-week doubleblind treatment phase (three weeks titration + eight weeks maintenance) of the PREVAIL study (ClinicalTrails.gov identifier: NCT01142193). Detailed methods of PREVAIL have been described previously [11] . Briefly, adults (18-75 years of age at time of entry into PREVAIL) with a confirmed diagnosis of refractory POS for at least one year on a stable regimen of 1-3 concomitant AEDs were eligible to enroll in PREVAIL and continue into the OLE. Eligible patients had a minimum of eight POS and no more than 21 consecutive seizure-free days during the 8-week baseline period of PREVAIL. Seizures classified as simple partial with motor signs, complex partial, or partial with secondary generalization qualified patients to meet inclusion criteria. Patients could have had more than one seizure type.
Study design
Upon entry into PREVAIL OLE (following 11 weeks of USL255 or placebo treatment in PREVAIL), patients underwent a 3-week blindedconversion phase followed by a 52-week open-label phase. During blinded conversion, patients previously randomized to placebo in PREVAIL were titrated in 50-mg/week increments to 200-mg/day USL255, and patients previously randomized to 200-mg/day USL255 in PREVAIL continued treatment. Following blinded conversion, openlabel maintenance at 200-mg/day USL255 for eight weeks was required for all patients. After 11 weeks of the OLE (3-week blinded conversion + +8-week maintenance), USL255 dosages were allowed to be titrated up or down by 50 mg/week, up to a maximum daily dosage of 400 mg/day. Concomitant AEDs (except vigabatrin, felbamate, and topiramate) could be added, removed, or dose-adjusted (but not within 3 days of a change in USL255 dose) as long as patients remained on 1-3 concomitant AEDs. At the end of the 55-week OLE, patients were tapered off USL255 by 50 mg/week over the course of at least three weeks or, with physician approval, were converted directly to the equivalent daily dose of immediate-release topiramate without taper.
Assessments
The primary objective of the study was to evaluate the safety and tolerability of USL255 as adjunctive treatment in patients with POS. Primary endpoints examined included spontaneously reported TEAEs, clinical laboratory values, vital signs, physical/neurological examinations, and suicidality assessments via the Columbia Suicide Severity Rating Scale (C-SSRS). Treatment-emergent adverse events were summarized by frequency, treatment relatedness, and maximum severity. Post hoc safety analyses included incidence (new onset) of neurocognitive TEAEs for the first 11 weeks of USL255 treatment (for newly exposed patients [PBO-USL]) and for the duration of PREVAIL OLE.
The secondary objective of the study was to assess seizure frequency in patients with POS receiving open-label USL255. Secondary endpoints included various seizure frequency outcomes (documented through patient diaries), the median percent reduction from baseline in weekly POS frequency, and responder rate (proportion of patients with ≥25%, ≥50%, ≥75%, or 100% reduction from baseline in weekly POS frequency); analyses included all patient data regardless of trial completion. Baseline was defined as the 8-week baseline period prior to the start of PRE-VAIL. Patients were also evaluated for seizure-free intervals (defined as the percentage of patients who were seizure-free for an interval of 4, 12, 24, 36, or 48 weeks at any time during the study). For the efficacy analyses, treatment periods evaluated included the 3-week blinded conversion phase, the 52-week open-label phase, and the overall 55 weeks of PREVAIL OLE (blinded conversion + open-label). For the 52-week openlabel phase, seizure rates also were calculated during each consecutive 12-week interval. Post hoc efficacy analyses included median percent reduction from baseline in weekly POS frequency and responder rate by patient age (18 to b 35, 35 to b50, and ≥50 years of age) and by drug refractoriness. Based on a surrogate measure of drug refractoriness (the number of current and lifetime AEDs), patients were divided into two groups: patients with ≥2 concurrent AEDs and ≥4 lifetime AEDs were defined as having "highly" drug-resistant seizures, while the rest of the study population comprised the group of patients with "less" drugresistant seizures (one concurrent AED and/or b 4 lifetime AEDs) [12] .
Exploratory clinical-status endpoints included the clinician-reported Global Impression of Change (CGI-C) and the patient-reported Quality of Life in Epilepsy-Problems (QOLIE-31-P) questionnaires, both performed at baseline and week 55 or early termination (ET, if applicable). The CGI-C was used to evaluate patient clinical status by assessing seizure frequency and severity, occurrence of adverse events, and overall functional status. The CGI-C is a 7-point scale with lower scores indicating greater improvement; scores range from 1 = very much improved to 7 = very much worse. The QOLIE-31-P was used to evaluate change from baseline in QOL and was completed by patients in countries where it was available and validated for the spoken language(s). The QOLIE-31-P is composed of seven subscales (seizure worry, overall quality of life, emotions, energy, mental activity, medication effects, and daily activities), and higher scores indicate greater well-being.
Data analyses
Safety and tolerability, efficacy, and QOL analyses were performed using the intent-to-treat (ITT) population, defined as all patients who received at least one dose of USL255 in PREVAIL OLE. Subgroup analyses included patients who were randomized to USL255 in PREVAIL (USL-USL) and patients who were randomized to placebo in PREVAIL (PBO-USL). The 8-week baseline period prior to the start of treatment in PREVAIL was used as baseline for all PREVAIL OLE endpoints. Descriptive statistics were calculated for all assessments, and endpoints were summarized using an observed cases analysis.
Results
Demographics, patient disposition, and exposure
Of the 217 patients who completed PREVAIL (USL255, n = 103; placebo, n = 114), 210 (97%) chose to enroll in the OLE and were included in the ITT population. Patient demographics and baseline characteristics are shown in Table 1 . Overall, patients had difficult-to-treat seizures, as the mean duration of epilepsy was 21 years; 20% of the overall population had taken at least seven lifetime AEDs; and 74% were on an AED regimen with at least two concomitant AEDs. Carbamazepine was the most commonly used AED in this population (45.2%). This was followed by valproic acid and its derivatives (33.3%), lamotrigine (27.1%), levetiracetam (21.9%), phenobarbital (16.2%), oxcarbazepine (12.4%), lacosamide (10.5%), and others used by b 10%. Only modest differences were observed between the USL-USL and PBO-USL subgroups. A total of 150 patients (71%) completed PREVAIL OLE (76% USL-USL and 68% PBO-USL; Table 1 ). The most common reasons for discontinuation were voluntary withdrawal by the patient (11%) and AEs (9.5%), with more patients in the PBO-USL subgroup discontinuing because of AEs than those in the USL-USL subgroup ( Table 1 ). The mean duration of patient exposure to USL255 during PREVAIL OLE was 336 days for those given active treatment during PREVAIL (USL-USL) and 320 days for those who had been given placebo (PBO-USL). At the end of PREVAIL OLE, 84% of patients had been exposed to USL255 for more than 180 days. Similar percentages of patients assigned to receive USL255 or placebo in the PREVAIL study experienced a change in USL255 dose during the OLE (USL-USL subgroup, 72%; PBO-USL subgroup, 69%). The percentage of total patients having a dose increase (70%) was nearly double the number of patients having a dose decrease (33.3%). A total of 63 patients (30%) increased their dose to the 300-to 350-mg dose range, and 15 patients (7.1%) increased to the ≥400-mg USL255 dose at some point during PREVAIL OLE (two subjects violated protocol with a N 400-mg dose).
Safety and tolerability assessments 3.2.1. Adverse events
Over the course of the study, 146 patients (69.5%) reported at least one TEAE (Table 2) , 90% of which were described as mild or moderate in intensity. At least one treatment-related TEAE was experienced by 102 patients (48.6%). A total of 16 serious adverse events (SAEs) were reported by 14 patients (Table 2) , of which only two events were deemed related to USL255 treatment (cholelithiasis and volvulus, n = 1 [0.5% of all patients] each). Of the 9.5% of all patients who discontinued the PREVAIL OLE study because of adverse events, aphasia, asthenia, convulsion, and diarrhea were the only TEAEs leading to discontinuation in more than one patient (n = 2 [1%] each). For the most common TEAEs, aphasia, fatigue, and somnolence had higher incidences in patients newly exposed to USL255 in PREVAIL OLE (PBO-USL) versus those continuing treatment from PREVAIL (USL-USL) ( Table 2 ).
Neurocognitive adverse events
Over the 55-week treatment period, the incidence of any individual with at least one neurocognitive-related TEAE was 12.9% of the total population ( Table 3 ). The only neurocognitive-related TEAE that was deemed "severe" by maximum intensity was aphasia, which was experienced in 2 individuals newly exposed to USL255 in the PREVAIL OLE (PBO-USL subgroup, 1% of the total population). The incidence of neurocognitive TEAEs leading to study discontinuation was 2% of the total population, all of which occurred in four patients that received placebo during PREVAIL (PBO-USL: aphasia, n = 2; bradyphrenia, n = 1; cognitive disorder, n = 1). Incidences for individual neurocognitive TEAEs were all b3%, with the exception of aphasia (5.2%). Post hoc analyses compared the incidence of new onset neurocognitive TEAEs following early USL255 exposure vs. extended periods of exposure (Table 3 ). In patients newly exposed to USL255 (PBO-USL), the overall neurocognitive TEAE incidence was 9.9% during the first 11 weeks of PREVAIL OLE and 10.1% during the remainder of the study (last 44 weeks). In the USL-USL subgroup, the incidence was 8.1% during the first 11 weeks of exposure (during the PREVAIL study [11] ) and 6.1% during the remainder of treatment exposure (ie the 55 weeks of PRE-VAIL OLE, Table 3 ). Overall, the incidence of neurocognitive TEAEs remained relatively consistent over time as patients continued treatment, although rates were slightly higher for patients newly exposed to the study drug in PREVAIL OLE (10.1% for PBO-USL [last 44 weeks] vs. 6.1% for USL-USL [entire 55 weeks], Table 3 ). The incidence of any speech disturbance (aphasia, dysarthria, and/or speech disorder: PBO-USL: 6.3% for the first 11 weeks and 5.1% for the last 44 weeks; USL-USL: 2% [55 weeks]) was similar to the results for aphasia alone.
Additional safety and tolerability assessments
Safety concerns associated with long-term topiramate use include metabolic acidosis, kidney stones, decreased sweating, and increased body temperature [13] , and none were reported during the 55-week OLE. Although mean alkaline phosphatase, blood urea nitrogen, chloride, and creatinine levels were increased from baseline and bicarbonate levels were decreased from baseline, the changes were not significant or unexpected, as serum chemistry parameters can be affected by topiramate. Overall, urinalysis and mean hematology values were within reference ranges, with the exception of red blood cell distribution width (high at baseline [15%] and increased slightly from baseline [0.14%]). For vital sign assessments, 8 patients had a ≥20% clinically significant increase or decrease from baseline in systolic blood pressure (n = 2, either ≥150 or ≤90 mm Hg), diastolic blood pressure (n = 5, either ≥100 or ≤60 mm Hg), or heart rate (n = 1, either ≥120 or ≤50 beats per minute). Decreases in body weight have been reported with topiramate use [13] and were observed regardless of prior PREVAIL treatment (change from PREVAIL baseline in USL-USL subgroup: −5.4%, PBO-USL subgroup: −4.0%). For both the physical and neurological examinations, five patients (2.4% each) experienced clinically significant changes from baseline. Although no patients experienced suicidal behavior during PREVAIL OLE, one patient reported suicidal ideation. One death occurred during the OLE (ischemic stroke) and was deemed unrelated to USL255.
Efficacy assessments
Across the 55-week OLE study, the median percent reduction in weekly POS frequency was 56% for the total population. The median percent reduction from the PREVAIL baseline was 51% during the 3-week blinded-conversion phase and 59% across the 52-week openlabel phase of the OLE. During the 52-week open-label phase, seizure reduction was relatively consistent across all weeks, regardless of prior double-blind treatment (Fig. 1A) . Similar trends were observed for 50% responder rate (Fig. 1B) , which was relatively consistent for all patients across the first three weeks (52%), the 52-week open-label phase (62%), and the entire 55-week study (58%), regardless of prior treatment. The 25%, 50%, 75%, and 100% responder rates for all patients during the open-label treatment phase are presented in Fig. 1C . The proportion of patients with a 100% reduction in seizure frequency from baseline to completion or early withdrawal during the open-label phase was 5% (Fig. 1C) . However, patients did experience seizure-free intervals of varying durations during the 55-week OLE. The percentage of all patients who experienced seizure-free intervals of 4, 12, 24, 36, and 48 weeks was 51%, 19%, 11%, 7.2%, and 2.4%, respectively.
Efficacy by drug resistance and patient age
In post hoc analyses of efficacy by drug-resistant status compared to PREVAIL baseline, seizure reduction was observed early (during 3-week blinded-conversion phase) and remained relatively consistent across the study, regardless of whether patients were deemed to have highly drug-resistant seizures or less drug-resistant seizures ( Fig. 2A) . Seizure reduction during the entire OLE also was not greatly impacted by patient age; during the 52-week open-label phase, the rate of seizure reduction was similar among all age groups evaluated, although during the first three weeks of treatment, the rate was slightly lower in patients at least 50 years of age (Fig. 2B) . However, the number of patients in this age group (n = 31) was approximately one-third of that in the 18-to b35-year age group (n = 94) and 35-to b50-year age group (n = 84). Nearly identical trends were observed for 50% responder rate when evaluated by drug refractoriness (during 55-week OLE: highly drug-resistant seizures, 66.1%; less drug-resistant seizures, 47.9%) and patient age (during 55-week OLE: 18 to b35 years, 61.7%; 35 to b50 years, 56%; ≥50 years, 51.6%).
Clinical and quality-of-life assessments
For the subset of patients (n = 92) who had evaluable investigatorbased CGI-C ratings at week 55, 45 (49%) were rated as 'much improved' or 'very much improved' from baseline. In addition, these ratings were similar for all patients during PREVAIL OLE, regardless of prior doubleblind treatment during PREVAIL (45% USL-USL [n = 21] vs. 53.3% PBO-USL [n = 24]). A total of 88 patients completed the patient-rated QOLIE-31-P survey at week 55, with improvements from baseline in the mean overall score (5.0) and distress score (6.5, Fig. 3 ). The largest subscale change from baseline in all patients was observed for the seizure worry subscale (10.8, Fig. 3 ). Treatment with USL255 resulted All patients received USL255 during PREVAIL OLE. USL-USL subgroup defined as patients who were previously randomized to USL255 in PREVAIL. PBO-USL subgroup defined as patients who were previously randomized to placebo in PREVAIL. Abbreviation: TEAE, treatment-emergent adverse event. USL-USL (red) and PBO-USL (blue) subgroups are defined as patients who were previously randomized to USL255 or placebo, respectively, in PREVAIL.
in a positive change from baseline for all subscales, except for the medication effects subscale where there was a slight worsening in patients newly exposed to USL255 in PREVAIL OLE (PBO-USL, Fig. 3 ).
Discussion
The results presented here are from the OLE study of PREVAIL, which was a phase 3, randomized, placebo-controlled, double-blind, multinational study evaluating the adjunctive treatment of 200-mg USL255 in adults with refractory POS. Of the 217 patients who completed PREVAIL, 210 (97%) enrolled in the OLE study -a strong indicator of favorable outcomes. A total of 150 patients (71%) completed PREVAIL OLE, which is in the range of retention rates (40-87%) reported following one year of treatment in other open-label AED studies [14] [15] [16] [17] [18] [19] [20] . During PREVAIL OLE, patients could increase or decrease USL255 dosage to a maximum of 400 mg/day, though most patients remained below 300 mg/day. This suggests that 200-275 mg/day of USL255 may offer an optimal maintenance add-on dosage for most patients.
USL255 was generally safe and well tolerated during the year-long PREVAIL OLE. Approximately 70% of patients reported a TEAE, most of which were mild or moderate in intensity. The most common TEAEs during the PREVAIL OLE study were headache, weight decrease, somnolence, dizziness, aphasia, and fatigue, though no single AE was reported in more than 7.6% of all patients. These TEAEs are not unexpected, as most are known to be associated with topiramate use (headache, weight decrease, somnolence, dizziness, and fatigue) [13] and are similar to those reported in the 11-week PREVAIL study. The incidence of individual neurocognitive TEAEs was less than 3% of the total population, with the exception of aphasia (5.2%). Further, the low incidence of neurocognitive TEAEs in PREVAIL OLE was evident for the year-long study duration; the incidence was similar between the first 11 weeks and last 44 weeks in patients newly exposed to USL255 in PREVAIL OLE (PBO-USL) and in patients newly exposed vs. those exposed during PREVAIL (USL-USL). This low incidence is of particular interest, as neurocognitive TEAEs including speech disorders, psychomotor slowing, and disturbance in attention are associated with topiramate [13] . In addition, metabolic acidosis and kidney stones -both associated with long-term topiramate use [13] -were not observed in the yearlong PREVAIL OLE study. The low incidence of these TEAEs may owe to selection bias, as patients at higher risk for these types of AEs (e.g., elderly, mentally handicapped individuals) may have been less likely to participate in this long-term study; however, individuals were not intentionally excluded because of age or cognitive abilities. It is possible that AEs experienced during the study could have been due to concomitant medications, as AEs can often be additive or synergistic with polytherapy [21] ; the ability of patients to modify both the number and dosage of AEDs following 11 weeks in PREVAIL OLE may be reflected in the reduced percentage of patients whose TEAEs were deemed treatment-related (49%). The total of 9.5% of patients who discontinued because of an AE in this year-long study is in line with data in the literature from open-label studies evaluating AEDs in patients with POS. which range from 3.5-32% [14] [15] [16] [18] [19] [20] [22] [23] [24] [25] . However, it is important to note that direct comparisons across clinical trials are difficult because of differences in patient populations, trial design, and duration of treatment.
The secondary objective of the study was to assess seizure reduction. Adjunctive treatment with up to 400 mg of USL255 reduced weekly median POS frequency by 56% across the 55-week OLE study, and 58% of patients had at least a 50% reduction in seizure frequency (50% responder rate). These results resemble those observed in patients randomized to USL255 treatment in the 11-week PREVAIL study (median % reduction: 39.5%, 50% responder rate: 37.9%) [11] and in other 1-year OLE studies of AEDs (median % reduction:~38-67%, 50% responder rate:
38-53% [14, 15, 19, 20] ). Efficacy also remained consistent throughout the duration of PREVAIL OLE, as newly exposed patients (PBO-USL) had seizure reduction rates that, when compared with the PREVAIL baseline, were similar at each phase of PREVAIL OLE and also similar to rates observed for patients previously exposed in PREVAIL (USL-USL) [11] ; it is possible, however, that concomitant AEDs may have contributed. Post hoc efficacy analyses revealed that this long-term seizure reduction was observed between adults of various age groups, as well as between patients with less or highly drug-resistant seizures. Positive seizure reduction seen in a subgroup with highly drug-resistant seizures suggests that difficult-to-treat seizures may respond to treatment with USL255.
Quality of life in patients with epilepsy is widely recognized as a significant component of disease management [26] . Improvements in CGI-C and QOLIE-31-P also were reported for USL255 during PREVAIL OLE, and mean changes in quality of life were generally in range with QOLIE-31 results reported for other AEDs [15, 20] . For patients with evaluable CGI-C data at study completion, 49% were rated as 'much improved' or 'very much improved' by investigators. The 'seizure worry' QOLIE-31-P subscale, which assesses the impact of seizures on QOL, had the largest positive change from baseline in the total patient population during PREVAIL OLE. Moreover, USL255 did not negatively impact the daily activities, mental activities, energy, emotions, or overall quality-of-life subscales. Such enhancements in QOL may help to reduce the burden associated with inadequate seizure control.
Limitations of open-label studies include the lack of a placebo arm for statistical comparisons, which may impact interpretation of longterm efficacy and patient awareness of receiving an active drug, which may increase effects compared with randomized, double-blind studies. Moreover, OLE studies can introduce a potential risk of bias that favors the study drug when patients in the randomized patient sample from the initial double-blind study are not all included in OLE analyses. For example, while 97% of participants who completed PREVAIL entered PREVAIL OLE, the 12.9% who discontinued PREVAIL (16.9% receiving USL255, 8.8% receiving placebo) [11] may have done so because of AEs or a lack of efficacy. In addition, the potential effects of adjustments in concomitant medications on long-term efficacy cannot be controlled
for in an open-label study design. Despite these limitations, the longterm evaluation of USL255 in an open-label setting, which allows for dosage adjustments to both USL255 and concomitant AEDs, provides safety and efficacy data that better reflect clinical practice.
In regard to the post hoc analysis of efficacy by drug refractoriness, the authors acknowledge that the International League Against Epilepsy (ILAE) definition of drug-resistant epilepsy ("failure of adequate trials of two tolerated and appropriately chosen and used AED schedules") [27] was not used, as the PREVAIL OLE study design prevents verification of patient participation in two "adequate trials". Therefore, the definition for drug resistance in the post hoc analyses was based on clinical experience and a pharmacoeconomic study that classified 'patients with refractory seizures' as those on three or more AEDs [12, 28] . Despite the limitations of defining drug resistance, many patients responded favorably to addition of USL255. Overall, the proportion of patients with long-term seizure-free intervals of 4, 12, 24, 36, and 48 weeks were 51%, 19%, 10%, 7.2%, and 2.4%, indicating that a number of subjects demonstrated seizure freedom, especially in the earlier stages of the study. This emphasizes the importance of continuing to administer new AED combinations to subjects whose seizures have failed to improve with multiple AEDs in the past.
The PREVAIL OLE results are consistent with the positive results of the PREVAIL double-blind study results. Overall, the results of this 1-year PREVAIL OLE demonstrate that adjunctive treatment with up to 400 mg/day of USL255 has a favorable safety and tolerability profile in adults with refractory POS. USL255 led to reductions in seizure frequency that were similar at each phase of the year-long study -suggestive of efficacy that is consistent and long-lasting. Further, USL255 was efficacious in many patient subgroups, including those with the most difficult-totreat seizures. These data suggest that once-daily USL255, Qudexy® XR (topiramate) extended-release capsules, may be a safe and beneficial treatment option for the long-term management of epilepsy in a variety of adult patients with POS.
